Endogard Plus XL Tablets for Dogs

Composition

Each tablet contains:

Active substances:

Praziquantel 175 mg

Pyrantel embonate 504 mg

Febantel 525 mg

Excipients:

Oval, biconvex tablets with bevelled edges and scored on both sides. Slightly greenish-yellow.

The tablets can be divided into equal halves.

3

Pharmacological properties

4.1 ATCvet code: QP52AC55

4.2 Pharmacodynamics

The veterinary medicinal product contains anthelmintics active against roundworms and tapeworms. The veterinary medicinal product contains three active substances: febantel, pyrantel embonate (pamoate) and praziquantel, a partially hydrogenated pyrazino-isoquinoline derivative used widely as an anthelmintic for both human and veterinary use.

Pyrantel acts as a cholinergic agonist. Its mode of action is to stimulate nicotinic cholinergic receptors of the parasite, induce spastic paralysis and thereby allow removal from the gastro-intestinal (GI) system by peristalsis.

With the mammalian system febantel undergoes ring closure forming fenbendazole and oxfendazole. It is these chemical entities which exert the anthelmintic effect by inhibition of tubulin polymerization. Formation of microtubules is thereby prevented, resulting in disruption to structures vital to the normal functioning of the helminth. Glucose uptake, in particular, is affected, leading to depletion in cell ATP. The parasite dies upon exhaustion of its energy reserves, which occurs 2 – 3 days later. Praziquantel is very rapidly absorbed and distributed throughout the parasite. Both in vitro and in vivo studies have shown that praziquantel causes severe damage to the parasite integument, resulting in contraction and paralysis. There is an almost instantaneous tetanic contraction of the parasite musculature and a rapid vacuolisation of the syncytial tegument. This rapid contraction has been explained by changes in divalent cation fluxes, especially calcium.

In this fixed combination veterinary medicinal product pyrantel and febantel act synergistically against all relevant nematodes in dogs. In particular, the activity spectrum covers Toxocara canis, Toxascaris leonina, Uncinaria stenocephala and Ancylostoma caninum. The spectrum of activity of praziquntel covers also cestode species in dogs, in particular all Taenia spp. and Dipylidium caninum. Praziquantel acts against adult and immature forms of these parasites.

4.3 Pharmacokinetics

Perorally administered praziquantel is absorbed almost completely from the intestinal tract. After absorption, the drug is distributed to all organs. Praziquantel is metabolized into inactive forms in the liver and secreted in bile. It is excreted within 24 hours to more than 95% of the administered dosage. Only traces of non-metabolised praziquantel is excreted.

The pamoate salt of pyrantel has low aqueous solubility, an attribute that reduces absorption from the gut and allows the drug to reach and be effective against parasites in the large intestine. Because of the low systemic absorption of pyrantel pamoate, there is very little danger of adverse reactions/toxicity in the host. Following absorption, pyrantel pamoate is quickly and almost completely metabolized into inactive metabolites that are excreted rapidly in the urine.

Febantel is absorbed relatively rapidly and metabolized to a number of metabolites including fenbendazole and oxfendazole, which have anthelmintic activity.

3

Target species

Dogs

3

Indications

For the treatment of mixed infestations with the following roundworms and tapeworms in adult dogs:

Nematodes:

Ascarids: Toxocara canis, Toxascaris leonina (late immature forms and mature forms)

Hookworms: Uncinaria stenocephala, Ancylostoma caninum (adults)

Cestodes:

Tapeworms: Taenia spp., Dipylidium caninum

3

Dosage

For oral administration.

Dosage

The recommended dose rates are: 15 mg/kg bodyweight febantel, 14.4 mg/kg pyrantel and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 35 kg bodyweight.

Tablets may be halved to allow accuracy of dosing.

Administration and Duration of Treatment

No restriction of access to food is required either before or after administration of the veterinary medicinal product. The tablet(s) can be given directly to the dog or disguised in food.

To a correct dosage, bodyweight should be determined as accurately as possible. For the control of Toxocara, nursing bitches should be dosed 2 weeks after giving birth and every 2 weeks until weaning.

In the event of a heavy roundworm infestation, a repeat dose should be given after 14 days.

For routine control adult dogs should be treated every 3 months.

3

Contraindications

Do not use simultaneously with piperazine compounds.

Do not use in cases of hypersensitivity to the active substance or to any of excipients.

Do not exceed the stated dosage when treating pregnant bitches.

3

Adverse reactions

Dogs:

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for contact details.

3

Warnings

Special precautions for safe use in the target species:

This veterinary medicinal product is not recommended for use in dogs under 17.5 kg body weight.

Any part-used tablets should be discarded.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In the interests of good hygiene, persons administering the tablet directly to a dog or by adding it to the dog's food, should wash their hands afterwards.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3

Use during pregnancy, lactation or lay

Pregnancy:

Do not use in bitches during the first two-thirds of pregnancy.

Consult a veterinary surgeon before treating pregnant animals for roundworms.

Lactation:

The veterinary medicinal product may be used during lactation (see Sections 3.3 and 3.9).

3

Interactions

Do not use simultaneously with piperazine as the anthelmintic effects of pyrantel and piperazine (used in many worming veterinary medicinal products for dogs) may be antagonized.

Concurrent use with other cholinergic compounds can lead to toxicity.

3

Overdose

The veterinary medicinal product is well tolerated in dogs. In safety studies, doses of up to five times the recommended dose gave rise to occasional vomiting.

3

Special warnings

Fleas serve as intermediate hosts for one common type of tapeworm – Dipylidium caninum. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.

3

Withdrawal period

Not applicable.

3

Incompatibilities

None known.

3

Immediate packaging

Print and perforated Alu-Alu blister: 2 tablets (1 blister with 2 tablets), in a box.

Print and perforated Alu-Alu blister: 4 tablets (2 blisters with 2 tablets), in a box.

Print and perforated Alu-Alu blister: 10 tablets (1 blister with 10 tablets), in a box.

Print and perforated Alu-Alu blister: 12 tablets (2 blisters with 6 tablets), in a box.

Print and perforated Alu-Alu blister: 24 tablets (4 blisters with 6 tablets), in a box.

Print and perforated Alu-Alu blister: 30 tablets (3 blisters with 10 tablets or 5 blisters with 6 tablets), in a box.

Print and perforated Alu-Alu blister: 50 tablets (5 blisters with 10 tablets), in a box.

Print and perforated Alu-Alu blister: 60 tablets (10 blisters with 6 tablets or 6 blisters with 10 tablets), in a box.

Print and perforated Alu-Alu blister: 100 tablets (10 blisters with 10 tablets), in a box.

Print and perforated Alu-Alu blister: 102 tablets (17 blisters with 6 tablets), in a box.

Not all pack sizes may be marketed.

3

Storage

This veterinary medicinal product does not require any special storage conditions.

3

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

3

Disposal of unused product

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

3

Additional information

Vm 01656/4018

8 DATE OF FIRST AUTHORISATION

02 June 2011

9 DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

September 2024

10 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product not subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

3

Registration holder

KRKA, d.d., Novo mesto

3